NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Bivision Biomedical Technology (Nanjing) Co., Ltd.

Bivision Biomedical Technology (Nanjing) Co., Ltd.

Private
NanjingHealthcare & Life Scienceshttp://www.bivision.com.cn/

Last Round

Series B

May 19, 2026

Total Funding Raised

$99.7M

Company Overview

Bivision Biomedical Technology (Nanjing) Co., Ltd. is a biopharmaceutical company that develops radiopharmaceutical therapies for the treatment and diagnosis of cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials, Medical Imaging

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

targeted radiopharmaceuticalstheranosticsPSMA-targetingoncology drug discoveryLutetium-177precision medicineradiopharmaceutical therapymetastatic prostate cancerFAP targetingnuclear medicineclinical-stage biotechsmall molecule ligandmCRPCdrug developmentradioligand therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Bivision Biomedical Technology (Nanjing) Co., Ltd. Comps

Public and private peers based on sector, stage, and business model.

Bivision Biomedical Technology (Nanjing) Co., Ltd. comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Bivision Biomedical Technology (Nanjing) Co., Ltd. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BMay 19, 2026
Series A ExtensionJan 17, 2025
Series AJul 26, 2024
AngelAug 10, 2022
SeedSep 1, 2021

Bivision Biomedical Technology (Nanjing) Co., Ltd. Investors

Notable investors and investment history

Bivision Biomedical Technology (Nanjing) Co., Ltd. investors
InvestorRounds
IDG CapitalSeries B
Kaitai CapitalAngel, Seed
Lichen CapitalSeries A, Angel
Wuxi Capital Group Co.,LtdSeries B
Yijing CapitalSeed
Guohai Innovation Capital Investment ManagementSeries B
Gaorong CapitalSeries B, Angel

Bivision Biomedical Technology (Nanjing) Co., Ltd. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Bivision Biomedical Technology (Nanjing) Co., Ltd. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Bivision Biomedical Technology (Nanjing) Co., Ltd.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersNanjing
Year FoundedN/A
Last FundingMay 19, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.